The purpose of this study is to gauge interest in a peer support program to help individuals with chronic kidney disease who are pregnant or are contemplating pregnancy navigate decision-making and care management. This survey will help us understand patients' desires for such a program and ways it can be implemented to best serve their needs and preferences.

This study is looking at how work and family related responsibilities affect ability to teach for mothers who are also physicians.

A challenge in treating COVID-19 is early prediction of patient outcomes. Here, we develop a functional assay for patient risk stratification based on clinically observed, unique vascular signatures of COVID-19. We integrate data from this assay with patient process of care information to determine predictive metrics for risk stratification.

The purpose of this IRB approved Humanitarian Use of a device is to allow patients to be treated with LDL-Apheresis, using the LIPOSORBER® LA-15 system. This device is approved for adult and pediatric patients with Focal Segmental Glomeruloslerosis as a Humanitarian Use Device. Its effectiveness has not been demonstrated.

We are collecting data on children living with chronic kidney disease, including children on dialysis or with a kidney transplant, to learn more about what happens over time. The data collected will be used for research projects.

We have created this registry to provide an opportunity to study diagnostic capabilities, administration protocols and long-term effects of contrast-enhanced ultrasound (CEUS) of any organ.

Infections occurring in individuals with glomerular disease are preventable contributors to excess healthcare utilization, morbidity, and mortality, and are the leading cause of death in children with glomerular disease. Vaccination is a powerful and cost-effective method to attenuate infectious burden, and clinical guidelines recommend that patients with glomerular disease receive 23-valent pneumococcal (PPSV23) vaccine. The main objective of the study is to determine functional PPSV23 immunogenicity in a prospectively collected multicenter cohort of children with idiopathic nephrotic syndrome using measurements of anti-pneumococcal and opsonophagocytic antibody titers prior to, and 1, 3 and 12 months following PPSV23 vaccination.